Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
LY3410738
i
Other names:
LY3410738, LY 3410738, LY-3410738
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Eli Lilly
Drug class:
IDH1 inhibitor, IDH2 inhibitor
Related drugs:
‹
ivosidenib (34)
olutasidenib (9)
vorasidenib (6)
GSK321 (3)
AGI-5198 (2)
BAY1436032 (1)
NMS-173 (1)
HMPL-306 (0)
IDH1 inhibitor (0)
IDH305 (0)
KY100001 (0)
DS-1001 (0)
enasidenib (16)
TQB3455 (2)
AGI-6780 (0)
SH1573 (0)
ivosidenib (34)
olutasidenib (9)
vorasidenib (6)
GSK321 (3)
AGI-5198 (2)
BAY1436032 (1)
NMS-173 (1)
HMPL-306 (0)
IDH1 inhibitor (0)
IDH305 (0)
KY100001 (0)
DS-1001 (0)
enasidenib (16)
TQB3455 (2)
AGI-6780 (0)
SH1573 (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
IDH1 R132H
Acute Myelogenous Leukemia
IDH1 R132H
Acute Myelogenous Leukemia
venetoclax + midostaurin + LY3410738
Sensitive: D – Preclinical
venetoclax + midostaurin + LY3410738
Sensitive
:
D
venetoclax + midostaurin + LY3410738
Sensitive: D – Preclinical
venetoclax + midostaurin + LY3410738
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login